MYCN増幅は,IDH変異性グリオマにおける攻撃的なフェノタイプを定義する

Xujun Xie¹, Qin Yan¹, Fang Wang²

¹Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

The journal of pathology. Clinical research

|August 26, 2025

まとめ

MYCN増幅は,特に低度のIDH変異性膠原腫の予後を著しく悪化させる. MYCN状態を分類に組み込むことは,これらの脳腫瘍の予後精度を改善します.

科学分野:

神経腫瘍学
分子診断
癌の分類システム

背景:

WHOの分類では,分子変化がグリオマの診断に組み込まれています.
IDH変異性膠原腫におけるMYCN増幅の予後的な役割はよく定義されていません.
MYCNの増幅は他のがんの悪い結果と関連しています.

研究の目的:

IDH変異性膠原腫におけるMYCN増幅の予後的意義を調査する.
MYCN増幅が生存と腫瘍特性に与える影響を評価する.
MYCNの地位を組み込む洗練された格付けシステムを提案する.

主な方法:

IDH変異性膠原腫患者の190人を分析した.
光 in situ ハイブリデーション (FISH) を用いてMYCN増幅を決定した.
カプラン・マイヤーとコックス回帰による生存率の評価;腫瘍形態の評価.

主要な成果:

MYCN増幅は14.7%の症例で,より高いグレードとKi-67指数と相関しています.
MYCN増幅は,特に低度の膠原腫では,全生存率を著しく低下させた.
提案されたMYCNベースの格付けシステムは,予後分層化の改善を示した.
MYCNで増幅された症例の50%で観察された.

結論:

MYCN増幅は,IDH変異性膠原腫における重要な予後マーカーである.
特徴的な上皮組織学的特徴と関連している.
MYCN ステータスを分類に組み込むことは,グリオマの予後精度と臨床的意思決定を強化します.

キーワード:

IDH変異性結晶腫 MYCN について増幅するエピテリオイド予後について

さらに関連する動画

09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

11.3K

05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.7K

関連する概念動画

01:06

Induced Pluripotent Stem Cells

4.4K

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

4.4K

02:23

Abnormal Proliferation

4.6K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

4.6K

03:03

mTOR Signaling and Cancer Progression

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...